Cardium Therapeutics, Inc. Reconciliation of Non-GAAP Measure As of March 31, 2011 | |||||
Three Months Ended March 31, | |||||
2011 | 2010 | ||||
Net Loss | $ (1,688,640) | $ (1,039,816) | |||
Add (subtract) | |||||
Stock-based compensation expense | 22,519 | 120,479 | |||
Change in fair value of derivative liabilities | (88,170) | (437,370) | |||
Non-GAAP net loss | $ (1,754,291) | $ (1,356,707) | |||
